A Phase 1b open label study of the pharmacokinetics and safety of oral OCX063 in adults with chronic kidney disease

Pharmacokinetic (PK) profile of OCX063 including • Peak plasma concentration (Cmax) of OCX063 obtained directly from the plasma concentration data without interpolation. • Time to peak plasma concentration (tmax) of OCX063 obtained directly from the plasma concentration data without interpolation. • Area under the concentration-time curve of OCX063 from time 0 to infinity (extrapolated) (AUC0-inf) • Area Under the Plasma Concentration versus -Time Curve over a dosing interval (tau). Dosing interval is considered as actual time 24 hours (AUCtau) • Accumulation ratio based on Cmax (RCmax) • Accumulation ratio based on AUC (RAUC)

This is an open label study to measure the PK of oral OCX063, over 28 days of dosing in participants with chronic kidney disease (CKD). The study will be run in sequential cohorts, with the first 6 participants receiving a 50 mg dose of OCX063 per day and the following 6 participants receiving 100 mg OCX063 per day. An additional dose cohort of 25 mg or 75 mg may be added if PK data indicate that a lower dose may provide adequate exposure levels. Safety will also be assessed.